XTalks

JULY 25, 2022

Oncologists also test for breast cancer subtypes, which are based on genetic characteristics, to determine the most appropriate treatment. Epidermal growth factor receptor 2 (HER2)-positive breast cancer is one such type in which there is an overexpression of the HER2 protein. Vic-]Trastuzumab Duocarmazine Mechanism of Action.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

pharmaphorum

OCTOBER 2, 2020

All that the agency has is preliminary data from pre-clinical and early clinical studies suggesting the vaccine triggers the production of antibodies and T-cells that target the virus. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

Regulation 105

Regulation Vaccination Vaccine Protein 105

Scienmag

FEBRUARY 18, 2021

A new protein is developed to bring the tumor cells and cells of the immune system together and effectively kill tumor cells Credit: Cancer Biology & Medicine Several treatments for cancer have been devised by science, but unfortunately none of them are completely efficient or foolproof.

Antibody 69

Antibody Protein Medicine Development 69

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

RNA 105

RNA Genetics Dermatology Antibody 105

pharmaphorum

NOVEMBER 25, 2021

1.1.529 variant has more mutations affecting the spike protein targeted by vaccines than any other strain identified to date, although it’s not yet clear if it is more or less transmissible. — Tom Peacock (@PeacockFlu) November 23, 2021. .”

Vaccination 116

Vaccination Vaccine Protein Genetics 116

pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. About NVX-CoV2373.

Protein 52

Protein Vaccination Vaccine Immune Response 52

Medical Xpress

FEBRUARY 7, 2023

Patients usually receive FVIII that comes from donor blood or is produced using genetic engineering. However, about one third of those treated for severe hemophilia A develop antibodies (inhibitors) against FVIII.

Antibody 40

Antibody Genetic Engineering Development Engineer 40

XTalks

JUNE 16, 2021

The company’s candidate recombinant nanoparticle protein-based COVID-19 vaccine, NVX-CoV2373, is being evaluated in the PREVENT-19 (the PRE-fusion protein subunit Vaccine Efficacy Novavax Trial COVID-19) Phase III trial, which has close to 30,000 participants across 119 states in the US and Mexico.

Vaccination 98

Vaccination Vaccine Protein Trials 98

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . The partners want to focus on riskier, more complex structures of proteins to try to decipher them.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

Pharmaceutical Technology

MAY 3, 2023

The US Food and Drug Administration (FDA) has granted Tenaya Therapeutics’ gene therapy TN-201 a fast track designation for the treatment of myosin binding protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM). Tenaya’s treatment delivers a functional MYPC3 gene, restoring myosin-binding protein levels to normal.

Gene Therapy 242

Gene Therapy Gene Protein Trials 242

pharmaphorum

FEBRUARY 5, 2021

J&J’s vaccine works by using an adenovirus as vector to deliver the genetic code of the Spike protein found on the coronavirus to the body. This causes the body to make the Spike protein, then produce antibodies against it that confer protection if virus infection occurs after the vaccination.

Vaccination 84

Vaccination Vaccine Protein Medicine 84

Velocity Clinical Research

AUGUST 8, 2024

It’s been just over a year since the monoclonal antibody Lecanemab received traditional approval from the FDA as a treatment for Alzheimer’s disease. The presence of amyloid proteins has been known since the disease was named, and the initial thinking was that their build-up caused it. We can’t do that for Alzheimer’s yet,” he says.

Clinical Trials 105

Clinical Trials Clinical Trials Genetics Clinical Research 105

pharmaphorum

AUGUST 16, 2020

The fund has already been deployed to order Gilead’s antiviral drug Veklury (remdesivir) and apheresis equipment to collect antibodies from the blood of patients who have recovered from COVID-19.

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

pharmaphorum

JUNE 16, 2022

The phase 2 API-ADAD study, a pioneering investigation which has been running for more than a decade, looked at crenezumab’s ability to slow or prevent Alzheimer’s symptoms in a population of cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimer’s.

Trials 111

Trials Clinical Trials Clinical Trials Licensing 111

pharmaphorum

DECEMBER 1, 2020

They work by using a short length of genetic code that makes the body produce the “Spike” protein seen on the surface of the SARS-CoV-2 coronavirus. This encourages the body to produce antibodies that neutralise the virus in the event of an infection.

Vaccination 88

Vaccination Vaccine RNA Clinical Trials 88

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

The Pharma Data

AUGUST 18, 2020

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. The companies will collaborate on developing and manufacturing REGN-COV2. Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

The Pharma Data

APRIL 12, 2023

Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement Biogen Inc. Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ).

Antibody 40

Antibody Development Engineer Licensing 40

XTalks

JUNE 15, 2022

The Novavax candidate NVX-CoV2373 is a protein-based vaccine developed using recombinant nanoparticle technology. protein that triggers the immune system to generate antibodies against the virus. If approved, NVX-CoV2373 would become the first available protein-based vaccine against COVID-19 in the US.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

XTalks

JUNE 30, 2023

Hemophilia A is a rare genetic bleeding disorder that is caused by a mutation in the gene that encodes the key blood clotting protein factor VIII (FVIII). Severe hemophilia A is usually treated with FVIII replacement therapy or an antibody-based drug to improve the ability of blood to clot and reduce the likelihood of bleeding.

Gene Therapy 98

Gene Therapy Gene FDA Approval Antibody 98

Delveinsight

AUGUST 26, 2021

Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. Shape’s RNA editing technology could potentially modify the amount of a key regulatory protein in the body or treat genetic diseases. BlueWillow shared little data about how the vaccine performed in its interim analysis.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

The Pharma Data

APRIL 7, 2021

Anti-p53 antibodies are antibodies that mistakenly target a patient’s own tissues, leading to a growth of solid tumors. today announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. The assay is now available for all markets accepting the CE Mark.

In-Vitro 52

In-Vitro Antibody Genetics Protein 52

pharmaphorum

DECEMBER 22, 2020

Since then Barron has been busy signing deals for therapies that are validated genetically, hoping that this will make them more likely to succeed in the clinic. The antibody targets PVRIG, an inhibitory protein expressed on natural killer cells (NK cells) and T-cells.

Licensing 52

Licensing Licensing Genetics Sales 52

The Pharma Data

JULY 6, 2021

GlaxoSmithKline plc (LSE/NYSE: GSK) and Alector (Nasdaq: ALEC), today announced a strategic global collaboration for the development and commercialisation of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. ” Arnon Rosenthal, Ph.D.,

Genetics 52

Genetics Gene Antibody Development 52

The Pharma Data

JANUARY 7, 2021

He also noted innovations are occurring with protein degraders, antibody conjugates, nanobodies and multi-specific antibodies, specifically bi- and tri-specific. Another area where Sanofi is investing is through the Expanded Genetic Alphabet platform it gained at the end of 2019 through the $2.5

Protein 52

Protein Antibody Genetics Gene Therapy 52

XTalks

JANUARY 26, 2023

Diagnosis is confirmed by a differential complete blood count and genetic testing. Treatment selection is determined by age, disease severity, comorbidities and the presence or absence of certain genetic mutations. As with many cancers, CLL and SLL are more difficult to treat in the relapse/refractory setting.

FDA Approval 97

FDA Approval Life Science Clinical Trials Clinical Trials 97

The Pharma Data

NOVEMBER 30, 2020

CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix?M. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. The award is funding the U.S.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron.

Antibody 40

Antibody Trials Production Clinical Trials 40

The Pharma Data

DECEMBER 5, 2020

(NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells.

Antibody 40

Antibody Production Trials Medicine 40

pharmaphorum

AUGUST 7, 2020

Inhibition of LRRK2 activity may slow the progression of Parkinson’s disease in patients with and without known genetic risks based on restoration of lysosomal function. Function of lysosomes is impaired in Parkinson’s disease and may contribute to the neurodegeneration that causes the symptoms of the disease.

Bacteria 69

Bacteria Marketing Licensing Licensing 69

The Pharma Data

NOVEMBER 9, 2020

Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. About NVX-CoV2373.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 15, 2020

” BigHat Biosciences: BigHat Biosciences is an early-stage Bay Area startup reimagining antibody discovery and engineering to create better antibodies faster and undertake novel designs far beyond what’s possible today.

Life Science 52

Life Science Protein Antibody Scientist 52

XTalks

JUNE 9, 2022

What happens when the liver is unable to process bad cholesterol due to genetic factors? It is one of the common genetic causes of premature coronary heart disease. Evkeeza — generically known as evinacumab — is a monoclonal antibody. The ANGPTL3 protein inhibits the enzyme activity of lipoprotein lipase (LPL).

Trials 52

Trials Antibody Genetics Gene 52

XTalks

OCTOBER 8, 2024

SMA is a genetic neuromuscular disease causing progressive muscle weakness and loss of motor function. Apitegromab is a monoclonal antibody that selectively binds to and inhibits myostatin, a protein that limits muscle growth. Efforts to improve SMA detection and treatment are gaining momentum.

Trials 52

Trials Antibody Genetics Medicine 52

pharmaphorum

OCTOBER 6, 2020

These studies suggest BNT162b2 triggers the production of neutralising antibodies and T-cells that target SARS-CoV-2, the coronavirus that causes COVID-19.

Vaccination 59

Vaccination Vaccine RNA Immune Response 59

The Pharma Data

DECEMBER 8, 2020

Since partnering with Eli Lilly to produce the first monoclonal antibody therapy approved for mild-to-moderate COVID-19 patients, antibody discovery company AbCellera is going big on the Nasdaq. The assumption is SciNeuro will start with Parkinson’s disease and pain in addition to rare genetic diseases, after scaling up staffing. .

RNA 52

RNA Antibody Life Science Protein 52